Skip to main content
. 2017 Jul 24;7:6235. doi: 10.1038/s41598-017-06673-3

Table 2.

CXB use associated with early prevention of oral cancer (Group 1) occurrence in a retrospective cohort study.

Characteristic Without CXB use With CXB use p value
n (%) n (%)
Total subjects 554965 49209
Gender
    Male 275117 (49.57) 18067 (36.71) <0.0001
    Female 279848 (50.43) 31142 (63.29)
Age (years)
    18–39 356630 (64.26) 5864 (11.92) <0.0001
    40–59 163516 (29.46) 22661 (46.05)
    ≥60 34819 (6.27) 20684 (42.03)
Oral cancer
    No 553256 (99.69) 49094 (99.77) 0.0004
    Yes 1709 (0.31) 115 (0.23)
ICD-9-CM
    140 139 (8.13) 7 (6.09)
    141 493 (28.85) 40 (34.78)
    143 107 (6.26) 5 (4.35)
    144 43 (2.52) 1 (0.87)
    145 927 (54.24) 62 (53.91)
Preventive effect based on prescription record of CXB use 1.00 0.51 (0.42–0.62)*
Dose-dependent effect
    Dose (100 mg daily) 1.00 1.01 (0.77–1.34)
    Dose (100/200 mg daily) 1.00 0.55 (0.37–0.81)*
    Dose (200 mg daily) 1.00 0.28 (0.20–0.40)*
Ptrend < 0.0001
Time-dependent effect
    1–3 years 1.00 0.84 (0.66–1.07)
    3–5 years 1.00 0.65 (0.38–1.13)
    ≥5 years 1.00 0.33 (0.22–0.48)*
Ptrend < 0.0001

Hazard ratio was examined using a Cox proportional hazard model with adjustment for the age and gender in a cohort study followed up from 1997 to 2010.

Follow-up years after the first CXB use.

*p < 0.01.